KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Net Cash Flow (2016 - 2026)

Gilead Sciences filings provide 17 years of Net Cash Flow readings, the most recent being $229.0 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 95.43% to $229.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.5 billion, a 163.84% decrease, with the full-year FY2025 number at -$2.5 billion, down 163.84% from a year prior.
  • Net Cash Flow hit $229.0 million in Q4 2025 for Gilead Sciences, down from $2.2 billion in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $5.0 billion in Q4 2024 to a low of -$2.9 billion in Q2 2025.
  • Median Net Cash Flow over the past 5 years was $130.5 million (2022), compared with a mean of $77.8 million.
  • The widest YoY moves for Net Cash Flow: up 31614.29% in 2024, down 356.63% in 2024.
  • Gilead Sciences' Net Cash Flow stood at $985.0 million in 2021, then plummeted by 35.23% to $638.0 million in 2022, then crashed by 46.24% to $343.0 million in 2023, then surged by 1360.64% to $5.0 billion in 2024, then plummeted by 95.43% to $229.0 million in 2025.
  • The last three reported values for Net Cash Flow were $229.0 million (Q4 2025), $2.2 billion (Q3 2025), and -$2.9 billion (Q2 2025) per Business Quant data.